Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 1 (3)

Trial Status

Recruiting4
Not Yet Recruiting2
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07274267Not ApplicableRecruitingPrimary

Inspiratory Muscle Training in Patients With Inflammatory Myopathy

NCT07249060Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

NCT07188285Not Yet Recruiting

Mass Spectrometry-based Immune Profiling in Autoimmune Diseases

NCT06828042Phase 1Recruiting

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

NCT06821659Phase 1Not Yet Recruiting

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

NCT06524687Phase 1Terminated

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

NCT04917705Not ApplicableRecruiting

Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies

Showing all 7 trials

Research Network

Activity Timeline